XPhyto Therapeutics taps Knox Communications to carry out marketing and investor relations

XPhyto Therapeutics Corp (CSE:XPHY) (FSE:4XT) (OTCPINK:XPHYF) said Wednesday it has entered into an investor-relations consulting agreement with Knox Communications Inc (KCI) to carry out marketing and investor communication activities for the company. KCI's founder and principal, Knox Henderson, brings more than 25 years' experience in investor relations, corporate finance and communications for publicly listed companies, XPhoto noted in a statement. READ: XPhyto Therapeutics partners with German biotech firm to develop coronavirus screening test Henderson has advised a broad range of early and growth-stage companies in the life sciences, technology and resource sectors, it added. His most recent major engagement involves notable success in the Canadian junior capital markets. The company noted that Henderson was formerly a CSC-designated trader on the Canadian equities markets. XPhyto said the agreement became effective July 1 for a term of 12 months and that it has granted Henderson stock options to purchase 100,000 common shares at $2.50 apiece for a period of one year. The options will vest in four equal tranches over the term of the agreement beginning three months from issuance. Vancouver-based XPhyto is a biopharma, diagnostics and cannabis science company focused on formulation, clinical validation, and European imports, distribution and sales. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham